Background: LDL receptor-related protein 5 (LRP5) triggers the canonical Wnt pathway which participates in cell function regulation, including lipoprotein metabolism, macrophage mobility and phagocytosis, but its function in the heart is unknown. Purpose: The aim of this study was to investigate LRP5 and the canonical Wnt signalling pathway in myocardial injury after acute-myocardial infarction (MI). Methods: MI was induced in WT and LRP5-/-mice by coronary ligation. Infarct size, LRP5 and Wnt signalling proteins were measured. LRP5 and the different metabolic pathways involved in myocardial damage post-MI were analyzed in isolated cardiomyocytes, myofibroblasts and endothelial cells. Results: LRP5-/-mice have significantly larger infarcts than WT mice (20.8 vs 9.9 p,0.5) suggesting a protective role of LRP5/Wnt in injured myocardium. Furthermore, administration of a GSK3 inhibitor that activates the Wnt pathway downstream LRP5, induced smaller infarcts in LRP5-/-mice indicating that an active Wnt pathway plays a protective role in the myocardium. Hypoxia induced LRP5 overexpression in isolated cardiomyocytes and endothelial cells indicating that a defensive and protective expression of LRP5 is triggered in both cell types. Induction of MI in WT and in LRP5-/-hypercholesterolemic animals, common risk factor in patients with ACS, induced larger infarcts in both genotypes. In isolated cardiomyocytes, LDL induced LRP5 overexpression and Wnt pathway activation whereas LRP5-silencing blocked the pathway. Conclusions: LRP5 and the canonical Wnt pathway activation is a defensive pro-survival process triggered to protect the ischemic myocardium against different injury triggers, such as hypoxia and hypercholesterolemia to favour and restore cell viability.
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FGF10 is required to promote cardiomyocyte proliferation after myocardial infarction R. Sturny; S. Payan; RG. Kelly; F. Rochais Aix-Marseille University, IBDM CNRS-UMR 7288, Marseille, France
In mammals, cardiomyocyte proliferation decreases after birth resulting in severely limited regenerative capacities in the adult heart. Understanding the developmental processes controlling cardiomyocyte proliferation may thus identify new therapeutic targets to modulate the cell cycle activity of cardiomyocytes in the adult heart. We recently identified FGF10 as a regulator of regional cardiomyocyte-autonomous proliferation in the fetal heart and showed that overexpression of Fgf10 promotes cell cycle reentry of adult cardiomyocytes. These results identify FGF10 as a potential clinically relevant target for promoting adult cardiomyocyte cell cycle reentry after cardiac injury.
Using an experimental mouse model of myocardial infarction (MI), together with Fgf10 loss of function mouse models, we investigated the role of FGF10 in pathological conditions. We first demonstrated that myocardial infarction leads to increased Fgf10 expression levels in the injured ventricle. Using an Fgf10-LacZ enhancer trap mouse line, we showed that Fgf10 is upregulated in cardiomyocytes, suggesting a role for FGF10 in pathological conditions. In order to investigate a potential protective role of FGF10 under pathological conditions, adult transgenic mice with reduced Fgf10 expression were subjected to myocardial infarction. Three weeks after myocardial infarction, cardiomyocyte hypertrophy, cell proliferation and heart function were evaluated. Immunofluorescence experiments revealed that while altered Fgf10 expression as no impact on cardiomyocyte hypertrophy, it significantly decreases post-MI cardiomyocyte proliferation. In addition, preliminary echocardiography experiments indicate that post-MI cardiac function is further impaired when Fgf10 levels are reduced. Together these results suggest that under pathological conditions FGF10 may play a protective role by promoting cardiomyocyte proliferation. FGF10 is thus as a potential target to improve the limited innate regenerative capacities of the myocardium after injury.
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A new role for transcription factor EB (TFEB) in mouse epicardial development Epicardium is the source of smooth muscle cells of coronary vessels (vSMCs) and intracardiac fibroblasts. Several pathways promoting epithelial to mesenchymal transition (EMT) of epicardial cells and their differentiation in vSMCs and fibrobalsts have been identified, but little is known about the factors limiting these processes. A member of MiTF-TFE family of transcription factors, TFEB is now extensively being studied due to its ability to increase lysosomal biogenesis and autophagy in response to the lack of nutrients. Although other MiTF family proteins are known to regulate differentiation of several lineages, TFEB involvement in embryo development has not yet been studied. Our goal was to investigate the role of TFEB in mouse embryo development. Once we discovered Tfeb expression in epicardium, we aimed to understand its function during epicardial development.
To study Tfeb expression in the embryo, we used a transgenic mouse that expresses fusion protein TFEB-GFP. To evaluate the role of TFEB in epicardial development, we generated mice with epicardium-specific TFEB overexpression (Gata5-Cre+:Tfeb-3xflag) and knock-out (Gata5-Cre+: Tfeb flox/flox). Primary epicardial cells were cultured without or in the presence of vSMC differentiation-stimulating factor BMP4. Epicardial mesothelial cell line EMC was used for Tfeb silencing and overexpression experiments. Acquisition of myofibroblast (MF) phenotype was defined by the increased expression of vSMC (PDGFRb, a-SMA, transgelin) and fibroblast (PDGFRa, fibronectin) markers evaluated by immunostaining, Real-Time PCR and Western blot and increased cell migration capacity measured in wound healing assay. ChIP-Seq analysis was performed in EMCs overexpressing constitutively active TFEB. Tfeb is expressed in mouse epicardium at 11.5 and 13.5 dpc and is not detectable after 15.5 dpc. TFEB is present in epicardial cells, but not in epicardially derived cells (EPDCs), vSMCs and fibroblasts. The prolonged epicardial overexpression of Tfeb leads to embryonic lethality at dpc 15.5. Epicardium of transgenic embryos develops normally, but differentiation and migration of EDPCs are severely inhibited. 
